COVID-19 Vaccine Guidance

Vaccine Recommendations: Use of Moderna XBB.1.5 mRNA COVID-19 vaccine

Source: Ministry of Health, COVID-19 Vaccine Guidance, Version 8.0 – September 22, 2023.

Unvaccinated Individuals		
	$\textbf{Recommended Interval}^1$	Minimum Interval ²
6 months – 4 years	Moderna XBB.1.5 (25 mcg) 2 dose schedule 2nd dose, <i>56 days</i> after 1st dose 	Moderna XBB.1.5 (25 mcg) 2 dose schedule 2nd dose, 28 days after 1st dose
5 – 11 years	Moderna XBB.1.5 (25 mcg) - 1 dose schedule	
³ 12 years +	Moderna XBB.1.5 (50 mcg) – 1 dose schedule	
Previously Vaccinated Individuals		
	Recommended Interval ¹	Minimum Interval⁴
6 months – 11 years	 Moderna XBB.1.5 (25 mcg) 6 months (168 days) after last dose or confirmed SARS-CoV-2 infection 	 Moderna XBB.1.5 (25 mcg) 3 months (84 days) after last dose or confirmed SARS-CoV-2 infection
12 years +	 Moderna XBB.1.5 (50 mcg) 6 months (168 days) after last dose or confirmed SARS-CoV-2 infection 	 Moderna XBB.1.5 (50 mcg) 3 months (84 days) after last dose or confirmed SARS-CoV-2 infection

² Minimum interval as outlined by the Moderna XBB.1.5 product monograph.

³ When Pfizer or Moderna are used as 2-dose vaccine series, NACI states a preferential recommendation for individuals 12-29 years to use Pfizer due to the lower risk of myocarditis and/or pericarditis. NACI recommendations on use of the XBB.1.5 vaccine for those not previously vaccinated in this age category are still pending. Health care providers offering Moderna XBB.1.5 to those who are 12-29 years older and previously unvaccinated should inform their patients of this previous NACI recommendation until the Pfizer XBB product is authorized and/or the NACI statement on initiation of the vaccine series is issued.

⁴ A shorter interval (3 to < 6 months) may be used to support fall program implementation (NACI).